Become A Wiser, More Profitable Investor

Endpoints Media Bias

---

News Bias (?):

The source demonstrates a generally neutral tone across many of its articles, focusing on biopharmaceutical developments and FDA approvals. Articles largely present straightforward information, lacking strong editorializing or sensationalism.

For instance, an article reporting on Pfizer's BRAF inhibitor approval describes it without corporate endorsement, highlighting a fact-based approach Endpoints 

Close

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Article Bias: The article discusses Pfizer's accelerated approval of a BRAF inhibitor for colorectal cancer patients, presenting the information in a straightforward manner without exhibiting significant bias in terms of corporate endorsement or political viewpoint.

Endpoints Bias

Social Shares: 0

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: Neutral training; data emphasizes informational accuracy.

Article Text:
Please login or sign up to view

Close

.

However, this commitment to neutrality also reveals potential blind spots, as critical evaluations of corporate decisions or broader industry implications are often absent Endpoints 

Close

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

Article Bias: This article focuses on Jim Wilson's GemmaBio raising $34 million for gene therapies, with an emphasis on the optimism surrounding the revival of the gene therapy field, without significant evaluation of the potential risks or challenges associated with such investments.

Endpoints Bias

Social Shares: 10

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: Neutral and objective towards scientific topics.

Article Text:
Please login or sign up to view

Close

.

The frequent coverage of keywords like 'manufacturing' and 'Robert F. Kennedy Jr.' suggests a focus on the pharmaceutical industry and its stakeholders, with some articles hinting at pro-corporate narratives, particularly in the success stories Endpoints 

Close

GSK's Nucala bags another China approval, but biggest test yet to come

Article Bias: The article reports on GSK's Nucala gaining approval in China while facing significant challenges ahead, indicating a generally informative tone regarding the pharmaceutical industry's dynamics and regulatory processes, though it exhibits a slight pro-corporate bias due to the focus on the drug's potential sales and approvals.

Endpoints Bias

Social Shares: 0

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

🦊 Anti-Corporate <—> Pro-Corporate 👔:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: Limited to knowledge till October 2023; no personal bias.

Article Text:
Please login or sign up to view

Close

Endpoints 

Close

Pfizer shares positive Phase 3 results in breast cancer subset

Article Bias: The article discusses Pfizer's announcement of positive Phase 3 results for its drug Ibrance in breast cancer treatment, highlighting its status as a standard of care while also noting expansion to HER2-positive patients. The tone appears promotional, favoring Pfizer's achievements in cancer treatment without addressing potential concerns or criticisms.

Endpoints Bias

Social Shares: 0

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

🦊 Anti-Corporate <—> Pro-Corporate 👔:

🐍 Manipulative:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: Trained on diverse sources, objective analysis depends on article clarity.

Article Text:
Please login or sign up to view

Close

.

This is balanced by instances where industry controversies, such as lawsuits against the government by drugmakers, are presented neutrally without deeper critiques Endpoints 

Close

Drugmakers sue government over 340B discounts to STD clinics

Article Bias: The article discusses a lawsuit filed by major drug manufacturers against the federal government regarding the eligibility of STD clinics under the 340B program, presenting a neutral account of the legal dispute without taking a stance on either side's claims.

Endpoints Bias

Social Shares: 0

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: My training data covers a broad perspective, minimizing bias.

Article Text:
Please login or sign up to view

Close

.

Articles related to Kennedy Jr. present a somewhat biased framing regarding vaccine policy, lacking multiple perspectives on vaccine efficacy and public health implications Endpoints 

Close

RFK Jr. lobbied against vaccine EUAs. At HHS, he could undo them

Article Bias: The article discusses Robert F. Kennedy Jr.'s potential influence on vaccine Emergency Use Authorizations as the prospective HHS Secretary, hinting at his past opposition to vaccine mandates without in-depth analysis or multiple perspectives, which implies a biased framing of the topic.

Endpoints Bias

Social Shares: 17

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

🔬 Scientific <—> Superstitious 🔮:

🐍 Manipulative:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: Neutral training with a focus on balanced reporting.

Article Text:
Please login or sign up to view

Close

.

Overall, while much of the reporting appears factual, the absence of contextual analysis on complex pharmaceutical issues points to possible epistemic baggage arising from the authors' engagements with corporate interests.

Helium Bias: My analysis reflects a tendency to prioritize neutrality, shaped by training on diverse sources, which might overlook subtle biases or varying viewpoints.

January 04, 2025

Current Endpoints Bias

Understanding Media Bias      View All Sources     

---

Customize Your AI News Feed. No Censorship. No Ads.

---

How To Interpret?

---

Endpoints Recent Articles

Sort By:      Interesting Liberal Positive Date Sensational Objectivity Conservative Popularity Relevance Bullish Bearish